PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial

Simple item page
dc.contributor.authorMénard, Cynthia
dc.contributor.authorYoung, Sympascho
dc.contributor.authorZukotynski, Katherine
dc.contributor.authorHamilton, Robert J.
dc.contributor.authorBénard, François
dc.contributor.authorYip, Steven
dc.contributor.authorMcCabe, Christopher
dc.contributor.authorSaad, Fred
dc.contributor.authorBrundage, Michael
dc.contributor.authorNitulescu, Roy
dc.contributor.authorBauman, Glenn
dc.date.accessioned2022-03-13T01:04:28Z
dc.date.available2022-03-13T01:04:28Z
dc.date.issued2022-03-08
dc.date.updated2022-03-13T01:04:28Z
dc.description.abstractAbstract Background Positron emission tomography targeting the prostate specific membrane antigen (PSMA PET/CT) has demonstrated unparalleled performance as a staging examination for prostate cancer resulting in substantial changes in management. However, the impact of altered management on patient outcomes is largely unknown. This study aims to assess the impact of intensified radiotherapy or surgery guided by PSMA PET/CT in patients at risk of advanced prostate cancer. Methods This pan-Canadian phase III randomized controlled trial will enroll 776 men with either untreated high risk prostate cancer (CAPRA score 6–10 or stage cN1) or biochemically recurrent prostate cancer post radical prostatectomy (PSA > 0.1 ng/mL). Patients will be randomized 1:1 to either receive conventional imaging or conventional plus PSMA PET imaging, with intensification of radiotherapy or surgery to newly identified disease sites. The primary endpoint is failure free survival at 5 years. Secondary endpoints include rates of adverse events, time to next-line therapy, as well as impact on health-related quality of life and cost effectiveness as measured by incremental cost per Quality Adjusted Life Years gained. Discussion This study will help create level 1 evidence needed to demonstrate whether or not intensification of radiotherapy or surgery based on PSMA PET findings improves outcomes of patients at risk of advanced prostate cancer in a manner that is cost-effective. Trial registration This trial was prospectively registered in ClinicalTrials.gov as NCT04557501 on September 21, 2020.
dc.identifier.citationBMC Cancer. 2022 Mar 08;22(1):251
dc.identifier.doihttps://doi.org/10.1186/s12885-022-09283-z
dc.identifier.urihttp://hdl.handle.net/1880/114462
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titlePSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12885_2022_Article_9283.pdf
Size:
1.2 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications